{
    "ABS.MI": {
        "short_name": "ARTERRA BIOSCIENCE",
        "long_name": "Arterra Bioscience S.p.A.",
        "summary": "Arterra Bioscience S.p.A., a research-based biotech company, engages in the research and development of various ingredients and natural solutions. It develops technological platforms, extraction processes, and raw materials for use in the cosmetics, agriculture, and nutraceutics sectors. The company was founded in 2003 and is based in Naples, Italy.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MIL",
        "market": "it_market",
        "country": "Italy",
        "state": "NA",
        "city": "Napoli",
        "zipcode": "80142",
        "website": "http://www.arterrabio.it",
        "market_cap": 26430214
    },
    "CSP.F": {
        "short_name": "CASSIOPEA S.P.A.  EO 1",
        "long_name": "Cassiopea S.p.A.",
        "summary": "Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Italy",
        "state": "MI",
        "city": "Lainate",
        "zipcode": "20020",
        "website": "http://www.cassiopea.com",
        "market_cap": 471693184
    },
    "NP5.F": {
        "short_name": "NEWRON PHARMACEUT. EO-,20",
        "long_name": "Newron Pharmaceuticals S.p.A.",
        "summary": "Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its product pipeline comprises Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "Italy",
        "state": "MI",
        "city": "Bresso",
        "zipcode": "20091",
        "website": "http://www.newron.com",
        "market_cap": 42607928
    },
    "NWPHF": {
        "short_name": "NEWRON PHARMACEUTICALS S.P.A.",
        "long_name": "Newron Pharmaceuticals S.p.A.",
        "summary": "Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its product pipeline comprises Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "Italy",
        "state": "MI",
        "city": "Bresso",
        "zipcode": "20091",
        "website": "http://www.newron.com",
        "market_cap": 42075040
    },
    "NWRN.SW": {
        "short_name": "NEWRON PHARMA N",
        "long_name": "Newron Pharmaceuticals S.p.A.",
        "summary": "Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its product pipeline comprises Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Italy",
        "state": "MI",
        "city": "Bresso",
        "zipcode": "20091",
        "website": "http://www.newron.com",
        "market_cap": 45951648
    },
    "PHIL.MI": {
        "short_name": "PHILOGEN",
        "long_name": "Philogen S.p.A.",
        "summary": "Philogen S.p.A., a biotechnology company, develops biopharmaceuticals for the treatment of angiogenesis-related disorders. The company focuses on developing immunocytokines for oncology and in chronic inflammatory diseases. It is developing NIDLEGYTM (DAROMUN), an immunocytokine product used as a neoadjuvant intralesional treatment for melanoma patients with locoregional disease that is in phase III clinical trial for intralesional application and phase II clinical trial to treat non-melanoma skin cancer; FIBROMUN, a human immunomodulatory product consisting of the human anti-EDB antibody L19 to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and DARLEUKIN (L19IL2), a human immunostimulatory product consisting of the human anti-EDB antibody L19, which is in phase II clinical trial for the treatment of metastatic non-small cell lung cancer. The company is also developing DODEKIN, a human immunostimulatory product that comprises vascular targeting antibody fused to the human cytokine interleukin-12 that is in phase I clinical trial to treat advanced solid carcinomas; DEKAVIL (F8IL10), an anti-inflammatory product, which is in phase 2 clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MIL",
        "market": "it_market",
        "country": "Italy",
        "state": "SI",
        "city": "Sovicille",
        "zipcode": "53018",
        "website": "http://www.philogen.com",
        "market_cap": null
    },
    "SKIN.SW": {
        "short_name": "CASSIOPEA N",
        "long_name": "Cassiopea S.p.A.",
        "summary": "Cassiopea S.p.A., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing medical dermatology products worldwide. It offers Winlevi, an antiandrogen, which has completed Phase III clinical trial for the topical treatment of acne; Breezula, a topical antiandrogen that is in Phase II clinical trial to treat androgenic alopecia; CB-06-01, a topical antibiotic, which is in Phase II clinical trial for the treatment of acne, including strains resistant to other antibiotics; and CB-06-02, a novel integrin activator that has completed Phase II clinical trial to treat genital warts. The company was formerly known as Cosmo Dermatos S.r.l. Cassiopea S.p.A. was founded in 2013 and is based in Lainate, Italy.",
        "currency": "CHF",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "Italy",
        "state": "MI",
        "city": "Lainate",
        "zipcode": "20020",
        "website": "http://www.cassiopea.com",
        "market_cap": 516000000
    }
}